• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Convalescent Plasma Decreases Mortality for Non-Intubated Patients with Severe COVID-19

May 27, 2020

Based on a preliminary propensity score-matched control study, convalescent plasma is beneficial for non-intubated patients with severe COVID-19. At the Mount Sinai Hospital in New York City, 39 hospitalized patients (average age, 55 years; 64% male) with severe to life-threatening COVID-19 were transfused with two units of convalescent plasma (SARS-CoV-2 anti-spike antibody titer of >1:320 dilution) and were retrospectively matched 1:4 with control patients with similar clinical characteristics and treatment regimens . On the day of transfusion, 87% of the plasma recipients required supplemental oxygen via non-invasive delivery, and 10% were mechanically ventilated. The median follow-up time was 11 days and 9 days for the plasma recipient group and control group, respectively. Based on covariate-adjusted Cox-survival analysis, improved survival was observed in non-intubated plasma recipients (hazard ratio, 0.19; 95% CI: 0.05-0.72; p=0.015) but convalescent plasma did not appear helpful for the intubated plasma recipients (hazard ratio, 1.24; 95% CI: 0.33-4.67). Furthermore, no serious adverse events were related to plasma transfusion. Large randomized clinical trials are underway and necessary to fully assess the safety and efficacy of convalescent plasma. Data are needed to identify which patients will benefit from convalescent plasma transfusions.

Reference:

Liu STH, Lin HM, Baine I, Wajnberg A, et al. Convalescent plasma treatment of severe COVID-19: a matched control study. MedRxiv 2020.05.20

Filed Under

  • Coagulation & Plasma Transfusion
  • News

Recommended

  • Annual U.K. SHOT Report on Serious Hazards of Transfusions

  • A New Class of Drug to Treat Anemia in Patients with Chronic Kidney Disease

  • Positive Coombs Tests and RBC Transfusions in Patients with COVID-19

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley